Drug intelligence / Profile preview

JS203

Development stage: Phase 2
Lead developer: Junshi Biosciences
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

JS203 is a recombinant humanized anti-CD20/CD3 bispecific antibody developed for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma. It works by simultaneously binding to CD20 on B lymphoma cells and CD3 on T cells, enabling T cells to effectively kill lymphoma cells. Pre-clinical studies have shown significant anti-tumor effects with good tolerability.

Other names: anti-CD20/CD3 bispecific antibody JS203

Targets

CD20 (B-lymphocyte antigen CD20)CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on JS203.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JS203.

Explore the full profile